TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline in ECG Results: QTcF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Hematology Laboratory Test Results: Red Blood Cell Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum Concentration (Cmax) of KH176
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive rate of carcinoembryonic antigen (CEA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: positive rate of α-fetoprotein (AFP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: positive rate of carbohydrate antigen 19-9 (CA 19-9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: positive rate of carbohydrate antigen 125 (CA 125)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: positive rate of carbohydrate antigen 72-4 (CA 72-4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time of discharge from any ward of the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Plasma concentrations of paracetamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Left Ventricular Mass Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cutaneous microvascular reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cutaneous microvascular flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of HspE7 and Poly-ICLC
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Symptom Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination of bacteria in the nose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change to diameter of vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of Test Arm patients achieving target temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean door-to-Recanalization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of hemorrhagic conversion in each arm within 36 hours of Recanalization
Endpoint domain: Adverse events/effects
Primary endpoint: 5-7 year patency rate of the LITA graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Withdrawal intensity
Endpoint domain: Adverse events/effects
Primary endpoint: Time for Operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Urinary levels of BCAAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pressure measured in kilopascals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of epileptiform EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Apixaban concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Integrity of Motor circuit reorganization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Integrity of corticospinal tract white matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to entry into HIV care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain and range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma AUCinf for PF-06463922
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma Cmax for PF-06463922
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes to myocardial viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: early detection of myocardial necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of treatment with aMBMC
Endpoint domain: Adverse events/effects
Primary endpoint: Contrast medium filling of intracranial vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in a standardized cognitive measure
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: AUCinf of R- and S-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to Online Intervention Modules
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Corneal endothelial morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in mean diurnal intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALS Functional Rating Scale-Revised (ALSFRS-R)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Decremental responses on repetitive nerve stimulation (DRRNS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Joint pain and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time required for lung separation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of repositioning maneuvers of the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lung collapse scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Adverse Events (AEs) Per Infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and Severity of Cardiovascular Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Migraine Frequency at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Colonization of umbilical stump
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Myocardial Perfusion Score Index (MPSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average Change From Baseline for Pain Intensity at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Total Daily Dose of Postoperative Morphine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With at Least One Adverse Event of Congestive Heart Failure, Pulmonary Edema, or Cardiac Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Response of 25(OH)D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brief pain inventory score (BPI)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Left ventricular Global Longitudinal Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: early postoperative overall spatial distribution of pulmonary ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in Back Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Leg Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tibial anteroposterior axis relative to femoral anteroposterior axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence or frequency of adverse or severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Hypoxic-ischaemic brain injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Making at Least One Critical Error
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean peak increase of serum creatinine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants with Relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Hospital Anxiety and Depression Scale (HAD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nottingham Health Profile (NHP)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Zarit Scale
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: SF12
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Technology Acceptance Model (TAM)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Likert Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in neuropsychiatric symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ratio of Compound Muscle Action Potential Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PHQ2
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Goal Attainment Scale Lite
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: peri-implant disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of Renal toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of Bone toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement of ventriculoarterial coupling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of energy efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum bioavailability (AUC 0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient return to work (RTW)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Recovery of CRPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Peak-to-peak amplitude of the motor evoked potentials (MEPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Peak-to-peak amplitude of the H-reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Normalized Protein Catabolic Rate (nPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Expression of Fas protein in skin biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Strength and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing a Dose-Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: miss rate of colon polyp detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reoperation for postoperative bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative appearance of penile skin congestion and/or necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Penile edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penile re-retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area Under the Plasma Concentration Time-curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimate of the Terminal Elimination Half-life in Plasma (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of stroke, systemic embolism, major bleeding or death
Endpoint domain: Mortality/survival
Primary endpoint: Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-reported quit attempt
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Mean Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skin cancer risk assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage Change in Prefrontal Cortex (PFC) Cerebral Blood Flow (CBF) During High-Irradiance t-PBM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage Change in Prefrontal Cortex (PFC) Cerebral Blood Flow (CBF) During Middle-Irradiance t-PBM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage Change in Prefrontal Cortex (PFC) Cerebral Blood Flow (CBF) During Low-Irradiance t-PBM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage Change in Prefrontal Cortex (PFC) Cerebral Blood Flow (CBF) During Sham Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Tooth Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Clinical Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reductions in Viral Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in knee flexion range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of participants with abnormal laboratory values
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Partial and Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Accuracy and speed of eFAST exams
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of atherosclerosis biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PANSS-N
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Abnormality in Composition of Corneal Epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Abnormality in Pathologic Characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Hamilton Depression Rating Scale (HDRS-17) Score Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Montgomery-Åsberg Depression Rating Scale (MADRS) Score Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Suicidal Behavior or Actual Attempts Using the Columbia- Suicide Severity Rating Scale (C-SSRS) Over Time
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants Experiencing Grade 3 or Higher Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of Triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Willingness to use the take-home rapid drug test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HbA1c in %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of HPV viral DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: In-hospital Death
Endpoint domain: Mortality/survival
Primary endpoint: Clinical Embolic Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Metabolic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fear of activity scale in CAD (FactCAD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional capacity (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise test (Modified Bruce protocol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time with interpretable fetal heart rate tracing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity and specificity of confocal imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of AK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in the number of unprotected anal sex partners (and acts)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Proportion of regress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference Between the Number of Actuations Registered by Actuation Indicator Versus Actuations Dispensed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Change of TG (Triglyceride)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Change of HDL-C (High Density Lipoprotein Cholesterol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Change of LDL-C (Low Density Lipoprotein Cholesterol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Early cancer changes in the colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Decreased distress on Patient Health Questionnaire (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decreased distress on EMA reports
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decreased anxiety symptoms on the Generalized Anxiety Disorder Questionnaire (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in scores from baseline to Day 42 in SNAP-IV-C and Connors'3 Parent Rating Scales
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quantification of Lactobacillus brevis CD2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistency of Lactobacillus brevis CD2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fold Change From Baseline in Fecal Calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AUC48-72 for buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC72-96 for buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: RBC/Barrier Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nutrient Intake (Lutein and Zeaxanthin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax, Tmax, and AUC(0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-minute Walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Activity Enjoyment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of eligible children who receive systemic steroids within 60 minutes of ED arrival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angiographic binary restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Tumor Uptake of 64Cu-DOTA-trastuzumab After 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor Uptake of 64Cu-DOTA-trastuzumab After 48 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality of life during dialysis
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of patients with deep ulcer healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of patients with stricture healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients with complex perianal fistula healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area under the plasma concentration-time AUC (0-T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve AUC(INF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of 2009 Seasonal Influenza Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dose limiting toxicity assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Patient-reported TST
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status